The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC).
 
Steven J. Frank
Leadership - C4 Imaging; National Comprehensive Cancer Network
Stock and Other Ownership Interests - C4 Imaging
Honoraria - IBA
Consulting or Advisory Role - IBA
Research Funding - Affirmed Pharma; Hitachi
Patents, Royalties, Other Intellectual Property - I have developed patents at the UT MD Anderson Cancer Center. These patents have been licensed to C4 Imaging.
Travel, Accommodations, Expenses - Boston Scientific; National Comprehensive Cancer Network
 
Paul Busse
No Relationships to Disclose
 
David Ira Rosenthal
Consulting or Advisory Role - Merck
 
Mike Hernandez
No Relationships to Disclose
 
David Michael Swanson
No Relationships to Disclose
 
Adam S. Garden
No Relationships to Disclose
 
Erich M. Sturgis
Consulting or Advisory Role - Roche
 
Renata Ferrarotto
Consulting or Advisory Role - Answers in CME; Coherus Biosciences; Eisai; Elevar Therapeutics; Labcorp Drug Development; Prelude Therapeutics; Regeneron; Remix Therapeutics; Sanofi/Aventis
Research Funding - Ayala Pharmaceuticals (Inst); Gilead Sciences (Inst); ISA Pharmaceuticals (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Prelude Therapeutics (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties on UpToDate chapter on olfactory neuroblastoma, ~ 300 dollars per year
 
Gary Brandon Gunn
No Relationships to Disclose
 
Samir H Patel
No Relationships to Disclose
 
NANCY Y. LEE
Consulting or Advisory Role - Elsie Pharmaceuticals; Galera Therapeutics; Merck; Merck Serono; Mirati Therapeutics; Nanobiotix; Regeneron
Speakers' Bureau - Shanghai Joanne Medical LTD; Varian Medical Systems; Yingming Consulting
 
Alexander Lin
Honoraria - IBA
Consulting or Advisory Role - Galera Therapeutics; IBA
 
James W Snider
No Relationships to Disclose
 
Mark William McDonald
No Relationships to Disclose
 
Christina Henson
No Relationships to Disclose
 
Gopal Krishna Bajaj
No Relationships to Disclose
 
Noah Kalman
Consulting or Advisory Role - Naveris
 
Upendra Parvathaneni
No Relationships to Disclose
 
Sanford R. Katz
Consulting or Advisory Role - Alira Health; Galera Therapeutics; PRA Health Sciences; Primary Endpoint Solutions; Second Genome
Travel, Accommodations, Expenses - Galera Therapeutics
 
Robert Leonard Foote
Patents, Royalties, Other Intellectual Property - Bionix